Basit öğe kaydını göster

Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.

dc.contributor.authorKurul, S
dc.contributor.authorTas, Faruk
dc.contributor.authorAydiner, A
dc.contributor.authorTopuz, E
dc.contributor.authorCamlica, H
dc.date.accessioned2021-03-03T18:16:15Z
dc.date.available2021-03-03T18:16:15Z
dc.date.issued2003
dc.identifier.citationTas F., Camlica H., Kurul S., Aydiner A., Topuz E., "Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.", Clinical oncology (Royal College of Radiologists (Great Britain)), cilt.15, sa.3, ss.132-5, 2003
dc.identifier.issn0936-6555
dc.identifier.otherav_4e1ebb64-4ca1-4043-b12b-6f8f25b2a484
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/55808
dc.identifier.urihttps://doi.org/10.1053/clon.2003.0205
dc.description.abstractAim: The aim of the current trial was to assess the efficacy and toxicity of 3-weekly intravenous docetaxel and irinotecan in the treatment of patients with metastatic malignant melanoma.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleCombination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
dc.typeMakale
dc.relation.journalClinical oncology (Royal College of Radiologists (Great Britain))
dc.contributor.department, ,
dc.identifier.volume15
dc.identifier.issue3
dc.identifier.startpage132
dc.identifier.endpage5
dc.contributor.firstauthorID168243


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster